Zoetis agreed to acquire Norway-based PHARMAQ, the global leader in aquaculture health, from Permira-led investors for approximately $765M, expanding Zoetis into fish health and vaccines. Borderline by pharma vs. animal health classification — included as platform-level vaccine deal.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedNov 17, 2015
ClosedDec 23, 2015
Deal value$765M
Deal typeAcquisition/Merger
Therapeutic areaAquaculture (salmon and warm-water fish diseases)
IndicationsAquaculture (salmon and warm-water fish diseases)
Key assetsAquaculture vaccines and pharmaceuticals portfolio
MechanismVeterinary vaccines and parasiticides for fish health